Creutzfeldt-Jakob disease in a 52-year-old woman with florid plaques

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways.

Cell death discovery·2020

Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene.

Neuromuscular disorders : NMD·2019

Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice.

Clinica chimica acta; international journal of clinical chemistry·2019

Differential overexpression of SERPINA3 in human prion diseases.

Scientific reports·2017

[Focal myositis: An unknown disease].

La Revue de medecine interne·2017

Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy.

Clinical genetics·2017

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Lancet (London, England)·2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Poster Abstracts - Academy of Managed Care Pharmacy 2026.

Journal of managed care & specialty pharmacy·2026

WIN-MTB-2024002 - WIN International Molecular Tumor Board: A 52-year-old female with unmeasurable Stage IIIc colon cancer.

Oncotarget·2026

Not all prolific letter writers are alike.

World journal of surgical oncology·2026

Determinants of AI Scribe Adoption in Allied Health: Mixed Methods Study Guided by the Capability, Opportunity, and Motivation Model for Behavior Change.

Journal of medical Internet research·2026

Creutzfeldt-Jakob disease in a 52-year-old woman with florid plaques

Related Experiment Videos

Related Concept Videos

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways.

Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene.

Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice.

Differential overexpression of SERPINA3 in human prion diseases.

[Focal myositis: An unknown disease].

Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy.

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Poster Abstracts - Academy of Managed Care Pharmacy 2026.

WIN-MTB-2024002 - WIN International Molecular Tumor Board: A 52-year-old female with unmeasurable Stage IIIc colon cancer.

Not all prolific letter writers are alike.

Determinants of AI Scribe Adoption in Allied Health: Mixed Methods Study Guided by the Capability, Opportunity, and Motivation Model for Behavior Change.

Creutzfeldt-Jakob disease in a 52-year-old woman with florid plaques

Related Experiment Videos

Related Concept Videos

Related Articles